Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05611931 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05611931 · ClinicalTrials.gov record · last posted 2026-08-27

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Study acronym: XPORT-EC-042
StatusActive, Not Recruiting
PhasePhase 3
Started2023-04-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Protocol amendment history 3 changes detected by DataLookout

2026-08-28
Trial sites reduced: 204 → 199 locations
2026-05-30
Trial status changed: Recruiting → Active, Not Recruiting
2026-05-30
Trial sites reduced: 217 → 204 locations
Trial Details
NCT Number NCT05611931
Lead Sponsor Karyopharm Therapeutics Inc
Collaborators: GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group, Multicenter Italian Trials in Ovarian Cancer (MITO), Grupo Español de Investigación en Cáncer de Ovario, Hellenic Cooperative Oncology Group, Cancer Trials Ireland (CTI), Mario Negri Gynecologic Oncology group (MaNGO)
Conditions Endometrial Cancer
Enrollment 257 participants
Start Date 2023-04-18
Primary Completion 2026-08 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-27